Cargando…
Propranolol eye drops in patients with corneal neovascularization
RATIONALE: Studies performed in animal models of corneal neovascularization suggested the possible efficacy of a treatment with propranolol. Corneal neovascularization is one of the most feared complications of Stevens–Johnson syndrome that frequently involves ocular surface. We report the first 2 p...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250516/ https://www.ncbi.nlm.nih.gov/pubmed/30407290 http://dx.doi.org/10.1097/MD.0000000000013002 |
_version_ | 1783372929814233088 |
---|---|
author | Filippi, Luca de Libero, Cinzia Zamma Gallarati, Barbara Fortunato, Pina Piozzi, Elena |
author_facet | Filippi, Luca de Libero, Cinzia Zamma Gallarati, Barbara Fortunato, Pina Piozzi, Elena |
author_sort | Filippi, Luca |
collection | PubMed |
description | RATIONALE: Studies performed in animal models of corneal neovascularization suggested the possible efficacy of a treatment with propranolol. Corneal neovascularization is one of the most feared complications of Stevens–Johnson syndrome that frequently involves ocular surface. We report the first 2 patients with severe ocular neo-vascularization treated with different degrees of success, with propranolol eye drops. PATIENT CONCERNS: Two patients with corneal neovascularization complicating the Stevens–Johnson syndrome, not responsive to steroids and cyclosporine, were treated with propranolol eye drops. DIAGNOSES: Corneal neovascularization was detected by ophthalmoscopic evaluation. INTERVENTIONS: Topical treatment with propranolol eye drops at different concentrations. OUTCOMES: Both patients reported dramatic subjective benefits (reduction of photophobia and discomfort) without adverse effects, and in the patient with a less advanced disease, an objective reduction of neovascularization and an improved visual acuity was observed. LESSONS: This experience suggests that propranolol might be an inexpensive, safe and effective treatment in counteracting the progression of corneal neovascularization. |
format | Online Article Text |
id | pubmed-6250516 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-62505162018-12-10 Propranolol eye drops in patients with corneal neovascularization Filippi, Luca de Libero, Cinzia Zamma Gallarati, Barbara Fortunato, Pina Piozzi, Elena Medicine (Baltimore) Research Article RATIONALE: Studies performed in animal models of corneal neovascularization suggested the possible efficacy of a treatment with propranolol. Corneal neovascularization is one of the most feared complications of Stevens–Johnson syndrome that frequently involves ocular surface. We report the first 2 patients with severe ocular neo-vascularization treated with different degrees of success, with propranolol eye drops. PATIENT CONCERNS: Two patients with corneal neovascularization complicating the Stevens–Johnson syndrome, not responsive to steroids and cyclosporine, were treated with propranolol eye drops. DIAGNOSES: Corneal neovascularization was detected by ophthalmoscopic evaluation. INTERVENTIONS: Topical treatment with propranolol eye drops at different concentrations. OUTCOMES: Both patients reported dramatic subjective benefits (reduction of photophobia and discomfort) without adverse effects, and in the patient with a less advanced disease, an objective reduction of neovascularization and an improved visual acuity was observed. LESSONS: This experience suggests that propranolol might be an inexpensive, safe and effective treatment in counteracting the progression of corneal neovascularization. Wolters Kluwer Health 2018-11-09 /pmc/articles/PMC6250516/ /pubmed/30407290 http://dx.doi.org/10.1097/MD.0000000000013002 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 |
spellingShingle | Research Article Filippi, Luca de Libero, Cinzia Zamma Gallarati, Barbara Fortunato, Pina Piozzi, Elena Propranolol eye drops in patients with corneal neovascularization |
title | Propranolol eye drops in patients with corneal neovascularization |
title_full | Propranolol eye drops in patients with corneal neovascularization |
title_fullStr | Propranolol eye drops in patients with corneal neovascularization |
title_full_unstemmed | Propranolol eye drops in patients with corneal neovascularization |
title_short | Propranolol eye drops in patients with corneal neovascularization |
title_sort | propranolol eye drops in patients with corneal neovascularization |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250516/ https://www.ncbi.nlm.nih.gov/pubmed/30407290 http://dx.doi.org/10.1097/MD.0000000000013002 |
work_keys_str_mv | AT filippiluca propranololeyedropsinpatientswithcornealneovascularization AT deliberocinzia propranololeyedropsinpatientswithcornealneovascularization AT zammagallaratibarbara propranololeyedropsinpatientswithcornealneovascularization AT fortunatopina propranololeyedropsinpatientswithcornealneovascularization AT piozzielena propranololeyedropsinpatientswithcornealneovascularization |